Inclusion Criteria:

- Patients with 3rd line or > metastatic colon cancer

- Patients must have received or not be candidates for regimens containing 5‐ FU,
oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab

- No prior exposure to perifosine

- Adequate bone marrow, liver, and renal function

- Patients must have at least one measurable lesion

- Patients must agree to have extra blood drawn for PK analyses

Exclusion Criteria:

- Patients with prior exposure to perifosine.

- Patients receiving any other investigational agents or devices.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to perifosine (miltefosine or edelfosine).

- Patients with known dipyrimidine dehydrogenase (DPD) deficiency or prior severe
reaction to 5‐FU.

- Patients with known central nervous system CNS metastases.

- Patients with known HIV, Hepatitis B, or Hepatitis C seropositivity.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection and psychiatric illness/social situations that would limit compliance with
study requirements.

- Patients with a history of unstable or newly diagnosed angina pectoris, recent
myocardial infarction (within 6 months of enrollment), or New York Heart Association
class II‐IV congestive heart failure.

- Female patients who are pregnant or lactating are ineligible.